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Cardiovascular disease (CVD) is a leading cause of death worldwide.
Approximately 60% of patients treated with low-density lipoprotein
(LDL)-lowering drug treatments, with on-target plasma cholesterol levels, are
still suffering clinical acute ischemic events. Mechanisms, such as LDL
aggregation, underlie extracellular and intracellular cholesterol accumulation
in the vasculature. A peptide sequence (P3) of the low-density lipoprotein
receptor-related protein 1 (LRP1) efficiently protects LDL from
sphingomyelinase (SMase-) and phospholipase A2 (PLA2)-induced LDL
aggregation. The aim is to design families of peptide derivatives from P3 with
enhanced potency and proteolytic stability. New peptides are designed
through in silico conformational sampling and ApoB-100 molecular docking,
and are tested in dual (biochemical-cellular) screening assays. A total of 46
new peptides including linear, fragment, cyclic, and alanine scanning
derivatives are generated through two consecutive optimization rounds.
Structurally and functionally optimized peptides contain hotspot residues that
are replaced by alanine. This strategy confers an increased capacity to form
prone alpha-helix conformations crucial for the electrostatic interaction with
ApoB-100. These new compounds are highly efficient at inhibiting LDL
aggregation and human coronary vascular smooth muscle cell-cholesteryl
ester loading and should be studied in preclinical models of atherosclerosis.
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1. Introduction
Ischemic heart disease is the primary cause
of death in Western countries, and myocar-
dial infarction accounts for ≈50% of deaths
from this disease. The Framingham study
showed that cardiovascular risk positively
correlates with low-density lipoprotein
(LDL)-cholesterol and inversely with high-
density lipoprotein (HDL)-cholesterol.[1,2]
High levels of LDL-cholesterol induce al-
terations in the endothelium permeability,
which in turn promote LDL influx into the
arterial intima.[3] Intimal LDL-cholesterol
accumulation is a critical step in vascular
cholesteryl ester (CE) deposition, a pro-
cess that increases the tendency of the
atherosclerotic plaque to rupture, trigger-
ing thrombosis and the development of
ischemic cardiomyopathy.[4–6] Cholesteryl
esters in atherosclerotic plaques are de-
posited both extra- and intracellularly. Ex-
tracellular deposition of LDL-CEs, a central
initiating event in atherosclerosis, is medi-
ated by proteoglycans in the extracellular
matrix of the arterial intima. The electro-
static interaction between proteoglycans
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and LDL and the proteolytic/lipolytic actions of enzymes on LDL
are enhanced in the arterial intima and promote LDL retention
and aggregation.[7,8] Two of the main enzymes that act on intimal
retained LDL and play key roles in LDL aggregation in the arte-
rial intima during atherogenesis are sphingomyelinase (SMase)
and phospholipase A2 (PLA2).
[9–12] Aggregated LDL (agLDL) has
been detected and isolated from atherosclerotic plaques from an-
imal models and humans.[10,13] Unlike native LDL, agLDL is a
potent inducer of massive intracellular CE accumulation both
in macrophages and human coronary vascular smooth muscle
cells (hcVSMCs).[14–18] In hcVSMCs, we reported that agLDL is
actively taken up through the low-density lipoprotein receptor-
related protein 1 (LRP1) which, in turn, induces LRP1 expres-
sion, promoting a positive feedback loop that efficiently trans-
forms hcVSMCs into foam cells.[19,20] hcVSMC-foam cells syn-
thesize and release high amounts of tissue factor, which is cru-
cial for the prothrombotic transformation of the vascular wall and
thus for the progression of atherosclerosis to thrombosis.[21,22]
The relevance of this mechanism in atherosclerosis is evident
since vascular smooth muscle cells (VSMCs) are the main com-
ponent of the vascular wall and more than 50% of foam cells
previously considered to be monocyte-derived macrophages in
human atherosclerotic plaques originate from VSMCs.[23] To-
gether, these findings support the notion that the generation of
hcVSMC-derived foam cells through LRP1-mediated agLDL up-
take is a key mechanism underlying cholesterol accumulation in
vasculature susceptible to atherosclerosis. Our group has iden-
tified LRP1 cluster II, in particular the region Gly1127-Cys1140
(peptide LP3: H2N-GDNDSEDNSDEENC-NH2) that spans the
C-terminal half of domain CR9, as pivotal for binding to agLDL
and subsequent internalization of agLDL into human VSMCs.[24]
Moreover, we have shown that anti-LP3 antibodies reduce high
fat diet-induced atherosclerosis in a rabbit model.[25] In addi-
tion, we have shown that LRP1-derived peptides (the original LP3
and its retroenantiomer version-DP3) are protective against LDL
aggregation, even in conditions of extreme lipolysis due to the
maintenance of ApoB-100 conformation.[26] We showed that DP3
forms a complex with ApoB-100 and this molecular interaction
stabilizes ApoB-100 conformation. ApoB-100 conformation sta-
bilization might guarantee the structural preservation of surface
cholesterol-enriched environments, where sphingomyelin (SM)
is located. Structural preservation of cholesterol, a key regula-
tor of phospholipolysis, would protect SM from SMase activity.
As a result, LDL complexed with DP3 remains unaltered when
exposed to SMase. This scenario changes when LDL complexed
with DP3 is exposed to PLA2. The target for PLA2 is phosphatidyl-
choline (PC), a phospholipid associated with low-cholesterol en-
vironments. Therefore, PC is unprotected against the attack of
PLA2, which hydrolyses PC producing lysoPC and nonesteri-
fied fatty acids. Remarkably, LDL complexed with DP3 is pro-
tected against SMase and PLA2-induced aggregation even in con-
ditions of extreme phospholipolysis, indicating that the main-
tenance of ApoB-100 conformation is enough to prevent LDL
aggregation.
The main objective of the present study is to design and eval-
uate a series of antiatherosclerotic families of peptides with po-
tential for in vivo application.
Table 1. Parameters for validation of biochemical (SMase-TB and PLA2-TB)
and cell-based (SMase-CE/FC) assays. These parameters were obtained
from the mean and SD of the values obtained with positive (DP3) and
negative control (P321) in ten different experiments performed by qua-
triplicate (SMase-TB assay) or duplicate (PLA2-TB and SMase-CE/FC ra-
tio assays). SMase: Sphingomyelinase; PLA2: phospholipase A2; TB: tur-
bidimetry; CE: cholesteryl esters; FC: free cholesterol.
SMase-TB PLA2-TB SMase-CE/FC
CV interassay [%] 11.60 7.97 12.79
CV intra-assay [%] 6.24 6.32 8.47
Estimated Z-factor 0.86 0.60 0.75
2. Results
2.1. Feasibility of Biochemical and Cell-Based Assays for
Compound Screening
The scheme of the biochemical SMase and PLA2-induced LDL
turbidimetry (SMase-TB and PLA2-TB assays) and cell-based as-
says (SMase-CE/free cholesterol (FC) assay) is described in Fig-
ure S1 of the Supporting Information. The potential of these as-
says as screening tools was evaluated by calculating the intra-
assay and interassay coefficient of variation (CV) using a pos-
itive (DP3) and a negative control (P321) through several ex-
periments performed in quadruplicate (SMase-TB) or duplicate
(PLA2-TB and SMase-CE/FC) (Figure S2, Supporting Informa-
tion). As shown in Table 1, the assays have an interassay CV
< 15% and an intra-assay CV < 10%, showing the robustness of
the assays and their feasibility to be used as evaluation tools. In
addition, we calculated the Z-factor, a pivotal parameter for com-
parison and evaluation of the quality of the assays that reflects
both the assay signal dynamic range and the data variation asso-
ciated with the signal measurements and therefore suitable for
assay quality assessment.[27] The calculated Z-factor for the three
assays was between 0.5 and 1.0 (Table 1), indicating the suitabil-
ity of these assays for screening of the effect of compounds on
LDL aggregation and foam cell formation.
2.2. Computational Design and Screening of Peptides from the
First-Round Optimization
2.2.1. Computational Peptide Design
The computational approach used to design optimized peptides
yielded 20 exploratory compounds that were produced by solid-
phase peptide synthesis (summarized in Figure 1). The charac-
terization and sequence of designed peptides have been detailed
in Tables S1 and S2 of the Supporting Information, respectively.
Considering the lack of structural information about the LRP1
receptor, the ApoB-100 protein and the low reliability of the cor-
responding homology models currently available, the computa-
tional design of CR9-based peptide analogues was performed by
combining a ligand-based method that completely neglects re-
ceptor 3D information and relies only on the physicochemical
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Figure 1. Schematic representation of the designed peptide groups through the development of the first-round optimization. Ala: Alanine.
and dynamic properties of the ligands, with a structure-based
protocol, based on molecular docking approach.
The first molecular strategy was based on the hypothesis that
unbound biomolecules (i.e., proteins, nucleic acids, peptides,
small molecules) naturally adopt a variety of conformational
states, a subset of which are suitable to bind to their biologi-
cal partner.[28,29] An exhaustive conformational sampling of the
LP3 peptide was performed by molecular dynamics (MD) sim-
ulations. The most populated low energy states were extracted,
considered to the ones most similar to the bound state, and then,
if possible, conformationally restricted in cyclic analogues bymu-
tating two specific residues to cysteine, chosen as the most suit-
able residues for creating rigid rings with relatively low synthetic
complexity. Finally, this strategy led to six cyclic analogues mim-
icking low-energy near-native bound conformations of LP3 pep-
tide, namely peptides P1, P2, P3, P4, P5, and P6.
The second computational protocol emerged from the idea
that interacting partners that are involved in initial encounters
evolve toward the final specific complex by mutually adjusting
their interfaces.[30] In accordance to this, multiple molecular
docking simulations were performed taking into account several
alternative conformations of both the receptor and the ligand,
namely, ApoB-100 protein and LP3 peptide, respectively. Then,
the most favorable docking complex was submitted to molecular
dynamic simulations in order to favor the mutual adjustment of
the docking partners and explore active-like conformations of the
peptide. The most LP3 active-like conformation was conforma-
tionally restricted in a cyclic analogue that was named P7 peptide.
An additional 13 LP3 derivatives were designed based on the
careful evaluation of the final docking complexes, as described
below. The objective was to obtain a better understanding of the
mechanism of interaction between the original CR9 domain pep-
tide andApoB-100 protein. Although the protein–protein binding
interface involved many contacts distributed throughout the en-
tire surface, it is known that in many cases only a small subset
of individual amino acids, the so-called hotspots, contribute the
most to the free energy of binding.[31] Homology modeling and
molecular dynamics methods combined with molecular dock-
ing provided the structural model of LP3 peptide in complex
with ApoB-100 and offered a detailed insight into the mechanis-
tic basis of LP3 recognition by ApoB-100 protein.[26] Moreover,
this result facilitated the identification of several specific residues
(namely Glu6, Asp7, and Asp10) found to be deeply buried upon
binding. To confirm the key role of these residues, the suspected
hotspot residues in the P17 sequence were replaced by alanine
residues because of its small and nonreactive side chain, thus
obtaining several LP3 alanine scanning analogue peptides (P8,
P9, P10, P11, and P12).
Shorter peptide sequences, derived from the parent peptide
(LP3) were also analyzed. These peptides (P13, P14, P15, P16,
P17, P18, and P19) were useful to identify the minimal peptide
sequence length responsible for the inhibitory activity of LDL ag-
gregation.
Finally, the enantiomer version of LP3 peptide was explored
(P20 peptide), with an expectation of a lower inhibitory activity
against LDL aggregation but on the other hand a theoretical en-
hanced plasma stability given by the high proteolytic resistance
of d-amino acids containing peptides.[32]
2.2.2. Peptide Screening
SMase-TB: The inhibitory effect of these exploratory compounds
on SMase-induced LDL aggregation is shown in Figure 2A. Sur-
prisingly, P20 peptide, the enantiomer version of LP3, displayed
similar activity compared to the original peptide, which is encour-
aging given its expected higher plasma stability compared to the
LP3 peptide (all l-amino acids). Additionally, three out of seven
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Figure 2. Inhibitory efficacy of the peptides from the first optimization round on A) SMase-TB, B) PLA2-TB, and C) SMase-CE/FC assays. Data are
presented as mean ± SD. N = 8 (SMase-TB), N = 4 (PLA2-TB and SMase-CE/FC). P-values are calculated using the Mann-Whitney U test. *P < 0.01
versus negative control. Ala: alanine, der.: derivative.
cyclic peptide analogues tested had a similar (P3) or higher (P4
and P5) efficacy than LP3. Most of the smaller fragment com-
pounds showed lower inhibitory activity compared with the par-
ent peptide.
We found that P17maintained approximately the same activity
as LP3 despite of its smaller size (i.e., 9 instead of 14 residues), in-
dicating that P17 contains the essential motif to protect LDL from
SMase-induced LDL aggregation. This result opens the possibil-
ity to generate a new library of compounds based on the struc-
ture of P17. Most of the LP3 alanine scanning analogues (P9–
P12) showed similar or slightly lower inhibitory activity than LP3,
which suggest that none of the residues Asp7, Asn8, Glu11, and
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Figure 3. Schematic representation of the designed peptide groups through the development of the second-round optimization. Ala: Alanine.
Glu12 replaced by alanine have a key role in the binding of pep-
tide to LDL particles or that such mutations cause structural re-
arrangement of the peptide leading to an improvement in the
binding, despite the loss of some specific intermolecular con-
tacts. However, the replacement of Glu6 residue by alanine led
to a 30% reduction of the effects on LDL aggregation, as shown
by P8 peptide.
PLA2-TB: The inhibitory effect of the compounds on PLA2-
induced LDL aggregation is shown in Figure 2B. LP3 fragments
were almost completely ineffective against PLA2-induced LDL
aggregation with the exception of P19. In contrast to P19,
which maintains the same inhibitory activity to LP3 despite a
smaller size, P17 was ineffective against PLA2-induced aggre-
gation. Interestingly, P17 and P19 differ only in one aspartate
residue located at the N-terminal that is present in P19 but
absent in P17. This suggests that this aspartate residue has a
key role in the inhibitory activity against PLA2-induced LDL
aggregation. Similar to SMase-induced LDL aggregation, LP3
cyclic analogues and, in particular P3–P7, maintained a high
inhibitory activity against PLA2-induced LDL aggregation. While
all the LP3 alanine-scanning analogues showed a moderate
to high inhibitory activity against SMase, only P10 and P12
maintained high inhibitory activity against PLA2 modification.
These results indicate that a higher number of residues involved
in intermolecular contacts are required to protect LDL against
PLA2 than against SMase. In this regard, Glu
6, Asp7, and Glu11
residues appear to be essential for inhibitory activity against
PLA2 but not against SMase-induced LDL aggregation.
SMase-CE/FC: The effects of the compounds on hcVSMC-
cholesterol loading were evaluated by analysis of the intracellu-
lar cholesteryl ester/free cholesterol ratio using thin layer chro-
matography (TLC). A representative TLC is showed in Figure
S3 of the Supporting Information. hcVSMC exposed to LDL
(nLDL or SMase-LDL) had similar free cholesterol (FC) levels to
hcVSMC unexposed to LDL, indicating that LDL did not alter FC
content in these cells. Conversely, intracellular CEs detected in
these cells upon exposure to LDL derived exclusively from CE
supplied by LDL, as hcVSMC unexposed to LDL did not contain
intracellular CE. The TLC analysis shows the high efficacy of the
positive control and, in particular of DP3, to inhibit the intracel-
lular CE/FC ratio, an index of hcVSMC-foam cell formation. Sim-
ilar to the result in the SMase-TB assay, the LP3 enantiomer ver-
sion had the highest efficacy in the cell-based assay.
LP3 cyclic derivatives and LP3 alanine scanning derivatives
inhibited intracellular CE/FC to a similar extent to the SMase-
induced LDL aggregation, which is in line with the essential
LDL condition of aggregation as cause of hcVSMC cholesterol
loading.[16,17,19–22]
2.3. Computational Design and Screening of Peptides from the
Second-Round Optimization
2.3.1. Computational Peptide Design
The computational strategy used to design peptides in the sec-
ond round of optimization resulted into 26 peptides. This second
set of compounds was synthesized by means of solid-phase pep-
tide synthesis (summarized in Figure 3). The peptide sequences
and their characterization have been detailed in Tables S3 and S4
of the Supporting Information, respectively. Peptides were clas-
sified into the following families according to their molecular
design: LP3 cyclic derivatives, LP3 alanine scanning derivatives,
LP3 fragments, P17 linear d-derivatives, P17 cyclic derivatives,
P17 linear l-derivatives, and P17 alanine-scanning derivatives.
P17 was one of the most promising peptides found in the first
optimization round; therefore, it was chosen as the starting point
for the second optimization round. P17 was optimized by ap-
plying both ligand-based and structure-based protocols similarly
to the first optimization round. First, given the high inhibitory
activity against LDL aggregation observed for P20 peptide (the
enantiomer version of LP3 peptide) within the first optimization
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Figure 4. In silico conformational sampling of A) P17 and B) P21 peptides.
Both the representative structures and the corresponding population dis-
tributions of the three most populated clusters are reported.
round, the enantiomer version of peptide P17 was taken into
consideration for this second set of compounds (P21). Moreover,
given the higher anti-LDL aggregation activity of P19 compared
to P17, longer versions of P21 were also obtained by adding one,
two, or three residues to both the N- and C-terminus P21 end,
to give P22, P23, and P24. An exhaustive conformational sam-
pling of P17 and P21 peptides was performed by MD simula-
tions and the most populated low energy conformations were ex-
tracted. Similar to LP3, P17 peptide lacks well-defined secondary
structure elements; thus, the most populated conformation was
constrained leading to one cyclic analogue, namely P25. Inter-
estingly, unlike P17, P21 only assumed quasi-helical structures,
suggesting that an alpha-helix conformation could favor the inter-
action with ApoB-100 due to minimal conformational rearrange-
ments upon binding and the consequent reduced entropic cost
needed (Figure 4). On the basis of this hypothesis, the stabiliza-
tion of the helix could lead to a greater decrease in energy costs
and, therefore, favor the binding of the peptide to ApoB-100 pro-
tein. To favor low energy cost states, some of the P21 residues
were selectively mutated into analogues with similar physico-
chemical properties but a higher tendency to form alpha-helix
conformations (Ser to Ala and Asn to Gln).[33] This strategy led
to the design of eight P21 analogues (namely, P26, P27, and P28)
and five longer versions of P21 peptide (P29, P30, P31, P32, and
P33). Additionally, multiple molecular docking calculations were
also performed using several alternative conformations of both
P17 and P20 peptides as ligand structures. MD simulations were
run on the best-ranked docking poses to explore active-like con-
formations and design proper analogues. Based on the analysis
of the specific intermolecular interactions of P17 with ApoB-100
protein, one cysteine or one serine residue was added to the P17
peptide C-terminal end to obtain P34 and P35 peptides, respec-
tively. In order to confirm the essential role of several specific
residues found to be deeply buried upon binding, five P17 ala-
nine scanning analogues were generated, thus obtaining P36,
P37, P38, P39, and P40 peptides.
However, four P21 analogues were generated by studying the
favored orientation adopted by the peptide upon ApoB-100 pro-
tein binding. Interestingly, virtually all the negatively charged
side chains were oriented to the same face of the alpha helix
and, thereby, directly interacted with several positively charged
residues of ApoB-100. In this context, the optimization of elec-
trostatic interactions between the peptide and ApoB-100 could
reduce the free energy and favor the final binding. For this rea-
son, P21 peptide residues exposed to the solvent upon bind-
ing, namely, Ser5 and Asn9, were mutated to alanine, positively
charged residues or hydrophobic residues (as negative controls),
leading to the design of six new peptides (namely, P41, P42, P43,
P44, P45, and P46 peptides).
2.3.2. Peptide Screening
SMase-TB: Both SMase- and PLA2-induced assays clearly sug-
gested that the optimization of LP3 peptide by reducing its size
(P17) remained a promising approach. Nevertheless, additional
modifications were needed in order to achieve similar inhibitory
activity on both SMase- and PLA2-induced LDL aggregation. In
this regard the introduction of d-amino acids (second round) ap-
peared to be a promising strategy. The effects of the compounds
from the second optimization round on SMase-induced LDL ag-
gregation are shown in Figure 5A. Like P20, P21 (the enantiomer
version of P17) showed similar inhibitory activity compared to
its parent peptide. Both the linear derivatives (P34 and P35)
and the cyclic derivative (P25) had similar inhibitory effects
to P17.
Unlike the results obtained on LP3 peptides, many of the P17
alanine scanning analogues, such as P36, P37, P38, P39, and
P40, showed a significant decrease in the inhibitory activity com-
pared with P17. The replacement of a single residue by alanine,
led to a reduction of at least 30% in the peptide inhibitory efficacy
against LDL aggregation. This clearly suggested that all these
residues have a key role in the binding to LDL particles and that
the deletion of their side chain leads to the loss of some specific
intermolecular contacts as well as unfavorable structural rear-
rangements of the peptide in solution or upon ApoB-100 protein
binding.
Interestingly, the attempt of enhancing P21 inhibitory effects
by stabilizing the expected alpha-helix conformation (P26, P27,
and P28) proved to be successful since this increased the in-
hibitory effects on LDL aggregation. We also observed that the
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Figure 5. Inhibitory efficacy of the peptides from the second optimization round on A) SMase-TB, B) PLA2-TB, and C) SMase-CE/FC assays. Data are
presented as mean ± SD. N = 8 (SMase-TB), N = 4 (PLA2-TB and SMase-CE/FC). P-values are calculated using the Mann-Whitney U test. *P < 0.01
versus negative control. Ala: alanine, der.: derivative, scan: scanning, bind: binding, WT: wild.
addition of one, two or three residues to the original sequence do
not significantly change the overall inhibitory effects (as observed
in P22, P23, P24, P29, and P31) with the exception of P30, sug-
gesting that P26 could have the optimal sequence to guarantee
the highest inhibitory activity within LP3 analogues. Finally, the
introduction of positively charged or hydrophobic residues led
to insignificant or negative effects, as shown by P41, P42, P43,
and P44 peptides. Collectively, the results from this biochemical
screening shows that P21, P22, P23, P24, P26, P27, P28, P29, P31,
and P41 peptides are the more promising compounds.
PLA2-TB Assay: P17 alanine-scanning analogues (P36,
P37, P38, P39, and P40) were ineffective against PLA2-
induced LDL aggregation. However, some of the P17 d-
amino analogues (P22, P23, P24, P29, and P31) showed
maximal inhibitory activity on PLA2-induced aggregation
(Figure 5B).
Both SMase- and PLA2-induced assays clearly pointed to P22
and P31 peptides as the most promising LP3 derivatives com-
bining significant inhibitory activity on both SMase- and PLA2-
induced LDL aggregation with a theoretically increased plasma
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Table 2. Pearson and Spearman’s correlations between SMase-TB and
PLA2-TB for all peptides and peptides separated by control, first, and sec-
ond optimization round compounds. SMase: Sphingomyelinase; PLA2:
phospholipase A2; TB: turbidimetry.
Pearson Spearman’s
















Table 3. Pearson and Spearman’s correlations between SMase-TB and
SMase-CE/FC for all peptides and peptides separated by control, first, and
second optimization round compounds. SMase: Sphingomyelinase; TB:
turbidimetry; CE: cholesteryl esters; FC: free cholesterol.
Pearson Spearman’s
















stability if compared with LP3 peptide because of the use of
d-amino acids.
SMase-CE/FC: As shown in Figure 5C and Figure S3 (Sup-
porting Information), most of the P17 (d-amino acids containing
analogues) were highly effective for the inhibition of hcVSMC
cholesterol loading. In particular, compounds P22 and P31, pre-
viously selected as themore promising LP3 analogues because of
their high efficiency of inhibition of aggregation induced by both
SMase and PLA2, also showed high inhibitory effects in the in-
tracellular cholesterol accumulation. P22 and P31 inhibited LDL
aggregation and intracellular cholesterol loading to a similar ex-
tent than LP3 and substantially higher than P17 peptides.
2.4. Analysis of the Correlation between the Efficacy of the New
Compounds on SMase-TB, PLA2-TB, and SMase-CE/FC Assays
The correlations between the efficacy of compounds in the
SMase-TB and PLA2-TB assays and between the SMase-TB and
SMase-CE/FC assays are shown in Figure 6A,B, respectively.
Given the distribution of the variables, we first analyzed Spear-
man’s correlations. However, Pearson’s correlation gave similar
qualitative and quantitative results for both the correlation be-
tween the efficacy of compounds in the SMase-TB and PLA2-TB
assays (Table 2) and between the efficacy of compounds in the
SMase-TB and SMase-CE/FC assays (Table 3).
The strong correlation between the efficacy of the total com-
pounds in the SMase-TB and SMase-CE/FC assays (Pearson r =
0.820, P = 0.000; Spearman’s r = 0.790, P = 0.000) is in line with
the key role of LDL aggregation on hcVSMC-foam cell formation,
previously described by our group.[16,17,19–22] Taken together, our
results from molecular, biochemical and cell-based studies point
to P22 and P31 as the most promising peptides to be evaluated
in vivo.
3. Discussion
Currently, the prevention of atherosclerosis and other CVDs is
mainly based on lipid-lowering agents (e.g., HMG-CoA reductase
and PCSK9 inhibitors) that reduce blood cholesterol levels. Al-
though this reduction of plasma cholesterol levels undoubtedly
affects the amount of cholesterol retained and accumulated in
the vascular wall of the coronary vessels, it does not avoid the
risk and the mortality of CVD events. Indeed, the benefit of lipid-
lowering drugs, such as statin-based therapies is often not re-
lated to a sharp decrease in CVD mortality (acute myocardial in-
farction and angina pectoris) in atherosclerosis patients.[34] Pre-
vious studies from different groups, including ours, have high-
lighted the pathological relevance of blocking processes occur-
ring locally in the arterial intima such as LDL aggregation and
the uptake of aggregated LDL by smooth muscle cells.[20–22,25] We
recently showed that LRP1-derived peptides, LP3, and, in par-
ticular, its retroenantiomer version (DP3) efficiently preserved
LDL from SMase or PLA2-induced LDL aggregation through the
maintenance of ApoB-100 conformation.[26] We demonstrated
that the protective effect of these peptides derives from their ca-
pacity to establish electrostatic interactions with a specific highly
positive sequence located in the ApoB-100 C-terminal region.
In this study, we developed LP3 peptide derivatives combining
structural- and ligand-based computational designs with func-
tional biochemical and cell-based screening systems to obtain op-
timized peptides with similar activity to the original peptides.
3.1. Amino Acids with D-Chirality and a Tendency to Form
Alpha-Helix Conformation Promote the Formation of
Peptide/ApoB-100 Stable Complexes that Are Required to
Maximize Peptide Functional Activity
Peptides containing d-amino acids consistently showed far
higher inhibitory activity with respect to their l-amino acid coun-
terparts, as with P17 and P21, LP3 peptide, and P20 and P19 and
P22 compounds. This effect is hypothesized to be related to a
higher metabolic stability derived from their stronger resistance
to proteolytic degradation as well as to a higher binding affinity
to Apo-B100 protein or positive structural consequences of the
binding.
Another structural feature that was observed to confer higher
activity against LDL aggregation was related to the higher ten-
dency to form alpha-helix conformations that could favor the
binding of the peptide to ApoB-100 protein and increase its in-
hibitory activity against LDL aggregation, as was shownwith P21,
P26, P27, and P28.
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Figure 6. Graphs showing the scatterplot for the correlation A) between SMase-TB and PLA2-TB and B) between SMase-TB and SMase-CE/FC. Blue
squares label the compounds selected to perform studies in in vivo models.
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3.2. Additional Molecular Peptide Optimization Requirements
Are Needed to Reach Maximal Efficacy against Both SMase- and
PLA2-Induced LDL Aggregation
Despite having significant inhibitory activity on SMase-induced
LDL aggregation, virtually all the 9-residue peptides, such as P17,
its d-amino acid counterpart P21, and their analogues P26, P27,
and P28 were found to have a very limited or null activity upon
LDL aggregation induced by PLA2. By contrast, we found that
longer sequences with at least one additional residue in the C-
terminal or the N-terminal end conferred higher inhibitory ac-
tivity to the peptide in the PLA2 environment. This was notable
in P34 and P35, which were generated by adding a cysteine or a
serine, respectively, to the C-terminal end of P17 sequence and
in P19, which was generated by adding an aspartate to the N-
terminal end of P17 peptide. P19, in comparison to P17, showed
an inhibitory activity ofmore than 90%on both SMase- and PLA2-
induced LDL aggregation.
Considering the limited structural data currently available on
ApoB-100 protein and the dynamic arrangement upon LDL ag-
gregation, it is difficult to provide a comprehensive explanation of
the specific structural requirements of the different peptides for
the successful inhibition of LDL aggregation induced by SMase
or by SMase and PLA2. It may be reasonable to suggest that
the binding of any of the active peptides to ApoB-100 protein
promotes a certain conformational change on ApoB-100 itself
and that it the extent of this conformational change that is re-
lated to the specific effect on LDL aggregation observed for each
peptide. Additionally, shorter peptides, such as P17 or P21, may
be able to induce a limited conformational change sufficient to
block SMase, but not PLA2 affecting LDL particles. Conversely,
peptides composed of at least ten residues, (e.g., P19, P22 or
P31) succeed in stimulating a more significant conformational
change on ApoB-100 leading to the inhibition of both SMase
and PLA2-induced LDL aggregation. It is also important to note
that the different requirements for the peptide to be protective
against SMase and PLA2-induced LDL aggregation are related to
the different locations of SM (the substrate of SMase) and PC
(the substrate of PLA2) on the LDL surface.
[35] SM is protected by
these peptides against phospholipolysis as it is part of cholesterol-
enriched domains, whose structure, preserved through the for-
mation of peptide-ApoB-100 complexes, modulates SM lipolysis.
By contrast, PC is located outside of these cholesterol-enriched
domains, and, therefore, is not protected by this mechanism.
Thus, the preservation of LDL against PLA2-induced LDL aggre-
gation requires longer peptides that ensure ApoB-100 conforma-
tion in conditions of extreme lipolysis.
3.3. Targeting LDL Aggregation as a Therapeutic Strategy to
Inhibit hcVSMC-Cholesterol Loading
This study demonstrated a strong correlation between the in-
hibitory activity of peptides on SMase-induced LDL aggregation
and hcVSMC-cholesterol loading. These results are in line with
the pivotal role of agLDL on foam cell formation from smooth
muscle cells.[16–19] AgLDL is a key contributor of extracellular
cholesterol plaque burden since extracellular matrix proteogly-
cans and proteolytic enzymes of the arterial intima strongly pro-
mote agLDL formation.[9–12] In addition, targeting foam cell for-
mation confers atheroprotection.[36,37] AgLDL also upregulates its
own receptor, LRP1, initiating a potent cycle that promotes foam
cell formation and increases plaque cholesterol burden.[19,24,25]
At a clinical level plaque burden determines the rapid progres-
sion of asyntomatic to syntomatic plaques, as reported in a
prospective observational study performed in 1.345 patients from
13 centers and seven countries.[38] We previously reported that
aggregated LDL induces the production and secretion of tis-
sue factor, the main initiator of thrombosis, by human coro-
nary VSMC.[21,22] Recent studies report that susceptibility of LDL
to aggregate is associated with future coronary artery disease
events.[39] We recently reported that circulating levels of soluble
LRP1 (sLRP1) predict future cardiac events at ten years in the co-
hort REGICOR.[40] Together, these studies highlight the potential
relevance and clinical interest of these compounds in the treat-
ment of atherosclerosis and in themanagement of cardiovascular
disease.
3.4. Essential Features of Optimized Peptides Selected to be
Assayed in Preclinical Models of Atherosclerosis
On the basis of both two computational strategies, namely,
structure- and ligand-based drug design, 46 compounds were de-
signed according to the minimal energy status of the complex
and maximal stability. This facilitated peptide cycling with the fi-
nal aim of finding the minimal motif within LP3 peptide amino
acid sequence able to inhibit both SMase- and PLA2-induced LDL
aggregation. A key structural feature that confers high activity
against LDL aggregation is the tendency to form alpha-helix con-
formations that favor peptide/ApoB-100 protein complex forma-
tion and increase its inhibitory activity against LDL aggregation,
as shown with P21, P26, P27, and P28.
However, peptides composed of at least ten residues (e.g., P19,
P22, or P31) succeed in augmenting a more significant confor-
mational change on ApoB-100 leading to the inhibition of both
SMase- and PLA2-induced LDL aggregation.
Taking into account all these considerations, P22 and P31,
which are P17-derived d-amino acid analogues are highly effi-
cient in inhibiting both SMase- and PLA2-induced LDL aggre-
gation. These enzymes are extremely active in the intimal ex-
tracellular matrix and these compounds are relatively small and
expected to be highly stable against proteases. In this context,
compounds P22 and P31 are highly promising to be tested in
preclinical models of atherosclerosis.
3.5. Clinical Implications
Although statin-based therapy is generally well tolerated and
highly effective in lowering blood cholesterol levels, it can be
associated with various adverse events (e.g., intolerance, myal-
gia, myopathy, rhabdomyolysis, and diabetes mellitus)[41] and
with an increased incidence of diabetes.[42] Indeed, as diabetic
patients suffer a high incidence of atherosclerosis and cardio-
vascular pathology, the development of innovative drugs for the
treatment of atherosclerosis in these patients, or those with
high susceptibility of diabetes development, is becoming of vi-
tal importance. In this context, inhibiting vascular cholesterol
Adv. Therap. 2020, 3, 2000037 2000037 (10 of 13) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advtherap.com
accumulation by modulating not only LDL aggregation but also
aggregated LDL internalization by vascular cellsmay be a promis-
ing therapeutic strategy in the treatment of cardiovascular dis-
ease.
4. Experimental Section
Molecular Modeling—In Silico Conformational Sampling: The in silico
conformational sampling of LP3 peptide included a conjugate gradient
minimization, an equilibration, and 100 ns long implicit solvent MD simu-
lation using NAMD simulation package.[43] Thus, as the first preparation
step, an LP3 3D structure was created from scratch and parameterized
using AmberTool16 Leap module and ff12 AMBER force field.[44] Then, a
1000-cycle longminimization was performed applying harmonic restraints
to all nonhydrogen atomswith a force constant of 5 kcalmol−1 Å−2 in order
to remove initial intermolecular clashes. A 200 ps long equilibration was
run gradually heating the system to 56.85 °C and applying harmonic re-
straints with the same force constant as in theminimization but only to the
backbone atoms. During equilibration, the integration time step was set
to 2 fs and the nonbonding cut off distance to 12 Å. Then, an unrestrained
replica exchange molecular dynamics simulation in implicit water was run
consisting of 16 independent 100 ns long trajectories (replicas) performed
simultaneously at temperatures ranging from 26.85 to 339.85 °C. Finally,
10 000 snapshots were extracted from the 300 K trajectory and were conse-
quently clustered using the single linkage method by the cpptraj AMBER
tool. A representative structure of each cluster was selected and confor-
mationally constrained by mutating two specific residues to cysteine in
order to obtain LP3 cyclic derivatives in the first optimization round, via in-
tramolecular disulphide bridge formation. The same strategy was used to
perform the conformational sampling of P17 and P21 compounds within
the second optimization round.
Molecular Modeling—I ApoB-100 Molecular Docking: The structural
model of ApoB-100 in complex with LP3 peptide was built by rigid body
molecular docking simulation using the corresponding peptide con-
formers described above, as ligands, and ten different ab initio models
of ApoB-100 LDL receptor binding domain, generated as previously
described,[26] as receptors.
Starting from each ApoB-100 protein structure and LP3 peptide con-
former previously obtained, different independent docking simulations
were performed using SMINA, an energy minimization optimized fork of
the AutoDock Vina docking program.[45] All the ligands and the receptor
structures were converted into input files suitable for SMINA using pre-
pare_ligand4.py and prepare_receptor4.py scripts provided by AutoDock
Tools.[46] A cuboid grid box of roughly 60 × 60 × 60 size with a grid space
of 0.375 Å was adjusted around Apo-B100 3227IKFDKYKAEK3236 region, as-
sumed to be responsible for LP3 peptide recognition according to previous
studies.[26] Exhaustiveness, number of modes and energy range were set
to 32, 100, and 50, respectively.
Once all the docking simulations were run, the lowest energy-docking
pose of each conformer in complex with ApoB-100 protein was selected
and submitted to a postdocking MD-based structural refinement. Thus,
each docking model underwent a conjugate gradient minimization, equili-
bration, and 3 ns long implicit solvent MD simulation, using NAMD simu-
lation package. As in the first preparation step, the overall protonation and
parameterization of the system was performed using the Leap module of
AmberTool16 and ff12 AMBER force field. A 1.000-cycle long minimization
step was performed applying harmonic restraints to all backbone atoms
of the system (both receptor and ligand) with a force constant of 5 kcal
mol−1 Å−2. Then, a 200 ps long equilibration step was performed gradu-
ally heating the system to 300 K and applying harmonic restraints to the
backbone atoms of the protein and the ligand with a force constant of 5
and 2 kcal mol−1 Å−2, respectively. Finally, a 3 ns long MD simulation was
performed applying harmonic restraints only to the backbone atoms of the
receptor protein with a force constant of 2 kcal mol−1 Å−2. In all the sim-
ulations, SHAKE[47] was applied to restrain all bonds to hydrogen atoms
while a 2 fs simulation time step and a 12 Å cut off distance for long-range
interaction were set.
Finally, the binding stability of each conformer was assessed by comput-
ing its average root-mean-square deviation (LigRMSDavg) along the last
1.5 ns of the trajectory using ICM Browser Pro software (Molsoft, LLC, La
Jolla, CA).[48] Conformers with LigRMSDavg values lower than 2 Åwere pre-
dicted as stable binders, close to the peptide active state and thus selected
to be conformationally restrained, when possible, by mutating two specific
residues to cysteine in order to obtain LP3 cycled derivatives. A similar pro-
tocol was applied to obtain derivatives of the P17 compound, one of the
most promising LP3 derivatives obtained in the first optimization round,
within the second optimization round. As no feasible cycled derivatives
were produced during the second round, linear derivatives were gener-
ated from the selected conformers based on the visual inspection of the
specific intermolecular interactions of the docking partners.
Additionally, the most frequently buried residues upon binding, in
terms of accessible solvent area (ASA) within all the selected conformers
were identified and used to design additional LP3 and P17 linear deriva-
tives. The ASA value was calculated by ICM browser software.[48]
Peptide Synthesis: All the peptides were synthesized by Iproteos S.L
(Barcelona, Spain) by means of solid-phase peptide synthesis following
a 9-fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu) strategy. Syntheses
were performed manually on a 100 𝜇mol scale per peptide using Rink
amide ChemMatrix resin. Peptide elongation and other solid-phase ma-
nipulations were donemanually in polypropylene syringes, each fitted with
a polyethylene porous disk. Solvents and soluble reagents were removed
by suction. Washings between synthetic steps were done with dimethylfor-
mamide and dichloromethane using 5 mL of solvents per gram resin each
time. N𝛼 -Fmoc-protected amino acids (four equivalents) were coupled
using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium (four equiva-
lents), and N,N-diisopropylethylamine (eight equivalents). The extent of
the reaction was monitored using the Kaiser test. During couplings, the
mixture was allowed to react with intermittent manual stirring. The Fmoc
group was removed by treating the resin with 20% piperidine in DMF
(3 mL g−1 resin). The peptides were cleaved from the resin using a mix-
ture of trifluoroacetic acid, triisopropylsilane, and water (95:2.5:2.5). The
crude products obtained were purified in reverse phase using a semiprep
HPLC instrument equipped with a C18 column. The purity and identity of
the synthesized peptides were assessed by HPLC, HPLC-MS, and MALDI-
TOF analysis.
In silico designed and synthesized compounds (N = 46) were evaluated in
a double screening system: The efficacy of the compounds to inhibit LDL
aggregation was first monitored by turbidimetry. The turbidimetry assay
has been optimized for screening by 1) using the enzymatic (SMase or
PLA2) induction of LDL aggregation and 2) using LDL from a unique nor-
molipemic pool (Figure S1, Supporting Information).
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—LDL Isola-
tion and Purification: Human LDL (d1.019–d1.063 g mL
−1) was obtained
from pooled normolipemic human plasma by sequential ultracentrifu-
gation in a KBr density gradient. Briefly, very-low density lipoproteins
(VLDLs) were first discarded after spinning plasma at 50 000 g for 18 h
at 4 °C using a fixed-angle rotor (50.2 Ti, Beckman) mounted on an Op-
tima L-100 XP ultracentrifuge (Beckman). Subsequently, VLDL-free plasma
was layered with 1.063 g mL−1 KBr solution and centrifuged at 50 000 g
for 18 h at 4 °C. LDLs were dialyzed against 0.02 m Trizma, 0.15 m NaCl,
1 × 10−3 m EDTA, pH 7.5 for 18 h and then against normal saline for 2 h
at 4 °C. Finally, isolated LDLs were filter-sterilized (0.22 𝜇m Millex-GV fil-
ter unit, Millipore). Protein concentration was determined using the BCA
protein assay (Thermo Scientific) and the cholesterol concentration was
determined with a commercial kit (IL test Cholesterol, Izasa).
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—Exposure of
LDL to Sphingomyelinase (SMase) or Phospholipase A2 (PLA2) in the Pres-
ence and Absence of Peptides under Strictly Controlled Conditions: Human
LDL (1.44mgmL−1) were incubated with 40 U L−1 of Bacillus cereus SMase
(Sigma-Aldrich, Schnelldorf, Germany) or with 50 𝜇g L−1 of type II secre-
tory PLA2 from honey bee venom (Sigma-Aldrich, Schnelldorf, Germany)
in 20 × 10−3 m Tris buffer (pH 7.0) containing 150 × 10−3 m NaCl, 2 ×
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10−3 m CaCl2, and 2 × 10−3 mMgCl2 at 37 °C. LDL incubation with SMase
(24 h) or PLA2 (36 h) was performed in absence or presence of peptides
at peptide concentrations of 10 × 10−6 m (peptide/ApoB-100 ratio: 5/1)
on the basis of the results obtained in dose- and time-course previous
experiments.[26] LDL lipolysis was stopped by addition of EDTA (final con-
centration 10 × 10−3 m).
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—
Quantification of the Inhibitory Efficacy of Each Compound against
LDL Aggregation Induced by SMase or PLA2: The efficiency of peptides
to inhibit LDL aggregation induced by SMase or PLA2 was estimated by
turbidimetry measuring the absorbance at a wavelength of 405 nm. The
inhibitory activity was calculated according to Equation (1)
Inhibition activity = [1 − (a − b∕c − b)] ∗ 100 (I)
wherein
a corresponds to the absorbance value in the presence of nLDL particles,
LDL aggregating enzyme (i.e., SMase or PLA2) and test compound,
b corresponds to the absorbance value in the presence of only nLDL par-
ticles, and
c corresponds to the absorbance value in the presence of nLDL particles
and LDL aggregating enzyme (i.e., SMase or PLA2).
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—Cell-Based
Screening Assay: The efficacy of the peptides to inhibit LDL-induced intra-
cellular cholesteryl ester accumulation wasmonitored by determination of
intracellular CE/FC ratio. The cellular assay has been optimized for screen-
ing by 1) using the cells from a unique batch through all experiments and
2) testing LDL aggregation degree before adding LDL to the cell culture.
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—Quiescent
hcVSMCs: Cells of a single lot batch (61 646 600) were obtained from
ATCC (ATCC-PCS-100-021) to prevent variability derived from cell origin.
Quiescence was induced by maintaining the cell culture for 24 h in a
medium with 0.2% foetal calf serum or for 48 h in a medium with 0.4%
serum at 37 °C and 5%CO2. Serum-deprived cells between passages 4 and
8 were used for experiments. Cells at these passages appeared as a rela-
tively homogeneous population with a hill-and-valley confluence pattern.
Cell monolayers were grown in vascular cell basal medium (ATCC-PCS-
100-030) supplemented with vascular smooth muscle growth kit compo-
nents (ATCC-PCS-100-042). Quiescent cells were exposed for 2 h to LDL
previously treated with SMase for 18 h in the presence or absence of pep-
tides at a concentration of 10 × 10−6 m. The degree of aggregation of the
added LDL was assessed by turbidimetry measurements before the incu-
bation with the cells (Figure S4, Supporting Information). Cells were not
exposed to PLA2-treated LDL due to the high cytotoxicity of PLA2. Cells
were collected for lipid extraction followed by neutral intracellular lipid par-
titioning through thin layer chromatography and lipid band analysis and
quantification.
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—
Determination of Intracellular Cholesteryl Ester/Free Cholesterol Ratio:
Following the lipoprotein incubation period, hcVSMCs were washed
exhaustively: twice with phosphate buffered saline (PBS), twice with PBS
supplemented with 1% bovine serum albumin (BSA), and once with PBS
supplemented with both 1% BSA and 100 U mL−1 heparin); cells were
then harvested into 1 mL of 0.15 m NaOH. Lipids were extracted using
the Bligh and Dyer method with minor modifications.[17,19] The lipid
extract was dissolved in dichloromethane, applied to silica gel plates,
and separated by thin layer chromatography. Cholesterol and cholesterol
palmitate were run as standards of free and cholesteryl ester, respectively.
A primary solvent combination of heptane/diethylether/acetic acid
(74:21:4, v/v/v) was used as chromatographic mobile phase followed by
heptane alone. After lipid separation, the plates were dried and stained
as previously reported.[24] Finally, the spots corresponding to CE and
FC were measured by densitometry against the standard curve using a
GS-800 Calibrated Densitometer (Bio-Rad).
Biochemical/Cell-Based Screening Assays for Peptide Efficacy—Calculation
of the Inhibitory Efficacy of Each Compound against hcVSMC-Cholesterol
Loading: hcVSMC exposed to LDL (nLDL or SMase-LDL) showed similar
FC levels compared to hVSMC not exposed to LDL, indicating that LDL did
not alter FC content in these cells. Conversely, intracellular CEs detected
in these cells upon exposure to LDL derives exclusively from CE supplied
by LDL, as hcVSMC unexposed to LDL did not have intracellular CEs. The
inhibitory effect of the novel compounds on the intracellular cholesterol
accumulation was analyzed in terms of decrease in the ratio of intracellu-
lar CE and FC content of hcVSMC exposed to LDL and SMase-LDL.
The efficacy of each peptide to decrease the ratio of intracellular CE and
FC content of hcVSMC exposed to LDL and SMase-LDL was calculated
according to Equation (2)
Efficacy = [1 − (a − b∕c − b)] ∗ 100 (2)
wherein
a corresponds to the CE/FC ratio in hcVSMC exposed to SMase-LDL and
in the presence of the test compound,
b corresponds to the CE/FC ratio in hcVSMC exposed to nLDL in the ab-
sence of the test compound, and
c corresponds to the CE/FC ratio in hcVSMC exposed to SMase-LDL in the
absence of the test compound.
Statistical Analysis: Data were described as the mean ± standard de-
viation (SD). Comparisons among groups were performed using Mann-
Whitney U test. Correlation between continuous variables was analyzed
using both Pearson’s linear correlation coefficient and the Spearman’s rho
coefficient. Correlation was plotted using a scatterplot, identifying the val-
ues of each round. The interassay CV was calculated as the average coef-
ficient of variation form plate control means and the intra-assay CV was
calculated as the average coefficient of variation between duplicates. The
Z-factor was calculated as previously described.[27] The two-tailed signif-
icance level was set at <0.05. The statistical software package IBM-SPSS
(V25) was used for statistical analyses.
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the author.
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